Background: We conducted this meta-analysis to compare the efficacy and safety of PARP inhibitors with or without chemotherapy versus chemotherapy alone for advanced breast cancer. Methods: A meta-analysis and trial sequential analysis were performed using RevMan 5.2 analysis software. Results: Six eligible randomized clinical trials involving 2080 patients were included. Regimens containing PARP inhibitors were significantly associated with higher objective response rate, longer progression-free survival and overall survival. The PARP inhibitor regimen group had a significantly higher rate of grade ≥3 thrombocytopenia than the chemotherapy-only group. Conclusion: Regimens containing PARP inhibitors are effective and safe for BRCA-mutated advanced breast cancer patients. The efficacy appears to be only marginal in patients with BRCA status unselected.
CITATION STYLE
Yan, F., Jiang, Q., He, M., & Shen, P. (2021). PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: A meta-analysis. Future Oncology, 17(18), 2381–2393. https://doi.org/10.2217/fon-2020-1175
Mendeley helps you to discover research relevant for your work.